PITTSBURGH--(BUSINESS WIRE)--RHI Magnesita, the leading global supplier of high-grade refractory products, systems and solutions, is pleased to announce the completion of the acquisition of the US ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

STORY HIGHLIGHTS RHI Magnesita acquires Resco Group for $410 million. Resco Group manufactures refractory products for various industries. RHI Magnesita plans to upgrade Resco's plants and expand ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use ...

PARIS, Feb. 27, 2025 /PRNewswire/ -- The Calderys Group has announced a significant investment to build a new innovation ...

The Food and Drug Administration (FDA) has approved Stoboclo® (denosumab-bmwo), a biosimilar to Prolia® (denosumab), and Osenvelt® (denosumab-bmwo), a ...

The ongoing, open-label, multicenter Phase 1/2 dose-escalation and dose-expansion LINKER-MM1 trial is investigating linvoseltamab in 282 enrolled patients with relapsed/refractory MM. The Phase 1 ...

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2 ; DLBCL-an ...